# Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma

> **NCT00856245** · PHASE2 · COMPLETED · sponsor: **University of Kansas Medical Center** · enrollment: 21 (actual)

## Conditions studied

- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00856245
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00856245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00856245, "Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00856245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*